Ensign Peak Advisors
ADAP

Ensign Peak Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Ensign Peak Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-43,285
Closed -$345K – 1854
2020
Q3 		$345K Sell
43,285
-2,169
-5% -$19K ﹤0.01% 1597
2020
Q2 		$455K Buy
+45,454
New +$285K ﹤0.01% 1482

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ensign Peak Advisors's ADAP Position: Q4 2020 in Review

Ensign Peak Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 43,285 shares — an estimated $345K sold.

Ensign Peak Advisors first reported a position in ADAP in Q2 2020 and held it in 2 quarters. The position peaked at $455K in Q2 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • Ensign Peak Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Ensign Peak Advisors sold 43,285 Adaptimmune Therapeutics shares in Q4 2020, an estimated $345K.
  • Ensign Peak Advisors first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 2 quarters.
  • Ensign Peak Advisors's Adaptimmune Therapeutics position peaked at $455K in Q2 2020.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Ensign Peak Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.